Amivantamab combined with FOLFOX or FOLFIRI showed a 51% overall response rate in RAS/BRAF wild-type mCRC patients, with a ...
J&J shares positive long-term results of Rybrevant study for RAS/BRAF wild-type metastatic colorectal cancer at ASCO ...
With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...
Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations This work confirms the clinical utility of ctDNA for RAS/BRAF molecular testing to ...
Effect of patient age on efficacy of FOLFIRI plus cetuximab vs bevacizumab in 1st-line treatment of metastatic colorectal cancer: An analysis of FIRE-3 (AIO KRK 0306). This is an ASCO Meeting Abstract ...
Cancer genomic profiling is rapidly transforming the clinical management of cancer patients. Results from our study indicate that metastatic colorectal cancer patients with certain BRAF mutations ...
Promising early clinical data about the drugs ERAS-007 and ERAS-601 has led to a trial studying the combination of the two drugs in treating patients with RAS/MAPK pathway-driven cancers. The first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback